

May 15, 1971

Dr. Allen Borger
Associate Director
Pfizer Pharmaceuticals
Groton, Connecticut

Dear Allen,

Separately, I am sending you two boxes containing duplicate copies of the report of our studies of doxepin hydrochloride and doxepin pamoate using the EEG profile methods for determining bioavailability and dose equivalence. These may be filed and submitted as you wish. You will note that some of the actual EEG analyses may be obscured by the reproduction and binding process, but the originals are on file in my laboratory and will be made available as requested.

I am also sending you additional copies of the summary report and the data summaries. This is the material that will be most useful to you.

I am very pleased with the results, for the technique seems to provide clear answers with a minimum of population sampling.

Many thanks for your interest and encouragement.

Sincerely yours,

Max Fink, M.D.